Gene Therapy for Epidermolysis Bullosa: Sticky Business
- PMID: 27966558
- PMCID: PMC5167791
- DOI: 10.1038/mt.2016.199
Gene Therapy for Epidermolysis Bullosa: Sticky Business
Comment on
-
Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa.JAMA. 2016 Nov 1;316(17):1808-1817. doi: 10.1001/jama.2016.15588. JAMA. 2016. PMID: 27802546 Clinical Trial.
References
-
- Siprashvili, Z, Nguyen, NT, Gorell, ES, Loutit, K, Khuu, P, Furukawa, LKet al. (2016). Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa. JAMA 316: 1808–1817. - PubMed
-
- Uitto, J, Has, C, Vahidnezhad, H, Youssefian, L and Bruckner-Tuderman, L (2016). Molecular pathology of the basement membrane zone in heritable blistering diseases: the paradigm of epidermolysis bullosa. Matrix Biol; e-pub ahead of print 3 August 2016. - PubMed
-
- Wong, T, Gammon, L, Liu, L, Mellerio, JE, Dopping-Hepenstal, PJ, Pacy, Jet al. (2008). Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol 128: 2179–2189. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
